Background Primaquine is the only licensed drug for eradicating Plasmodium vivax
hypnozoites and, therefore, preventing relapses of vivax malaria. It is a vital component of …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Background There is a high risk of Plasmodium vivax recurrence in patients treated for
Plasmodium falciparum malaria in co-endemic areas. Primaquine radical cure has the …

Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …

Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria
despite increasing reports of treatment failure. We did a systematic review and meta …

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

Background Imperfect adherence is a major barrier to effective primaquine radical cure of
Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P …

Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but
the optimum duration of treatment and best partner drug are uncertain. A randomized …

Background The effect of primaquine in preventing Plasmodium vivax relapses from
dormant stages is well established. For Plasmodium ovale, the relapse characteristics and …

Background Primaquine has been the only widely available hypnozoitocidal anti-malarial
drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a …